This invention relates to the use of antibody therapy as a treatment substitute, or for treatment interruption, to treat HIV-1 infected patients. Specifically, the present invention relates to the use of antibody therapy, such as PRO 140 monoclonal antibody therapy, as a monotherapy for treatment of HIV-1 infected patients.